KEYNOTE-B49
What it tests: Pembrolizumab versus placebo, both combined with chemotherapy, in HR+/HER2− advanced breast cancer. Randomized, double-blind phase 3 study.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.